Across 30 European markets, the same newly approved medicine reaches about 86% availability in Germany but takes years longer to reach the slowest markets, often at a fraction of that coverage. Even the average launch delay, the gap between a […]
The world’s largest drug safety database, the WHO’s VigiBase, holds over 40 million adverse event reports contributed by more than 180 countries. The FDA’s FAERS system has accumulated over 28 million reports and receives more than 2 million new ones
As the life sciences industry continues its digital transformation, electronic labeling (e-labeling) is becoming an increasingly important part of regulatory compliance. Instead of relying solely on printed labels and paper Instructions for Use (IFUs), manufacturers can provide approved product information
The European Union’s In Vitro Diagnostic Medical Devices Regulation (IVDR 2017/746) introduced a more rigorous regulatory framework for in vitro diagnostic (IVD) devices. Replacing the In Vitro Diagnostic Directive (IVDD), it places greater emphasis on patient safety, clinical evidence, and
Vietnam is one of Southeast Asia’s fastest-growing healthcare markets. Rising healthcare expenditure, an aging population, increasing demand for advanced medical technologies, and continued investment in healthcare infrastructure have driven growth in the country’s medical device sector. Since Vietnam relies heavily
Bringing a medical device to market is only the beginning. Once a product is in use, manufacturers must continue monitoring its safety, performance, and real-world impact through post-market surveillance (PMS). Post-market surveillance enables manufacturers to identify emerging risks, address product
A single mistranslation in a patent claim can invalidate years of work and billions in R&D investment. When it comes to pharmaceutical patents in global markets, protection is only as strong as its weakest translation, its most vulnerable jurisdiction, or
A single mistranslated word in a clinical trial protocol can delay regulatory approval by months, while inconsistent terminology across submissions can derail market access entirely. In life sciences, regulatory translation isn’t about converting words between languages, but about maintaining scientific
Most pharmaceutical companies expanding into the Asia-Pacific make the same mistake of treating APAC clinical trials like extensions of their Western operations, just with different languages. Then they wonder why regulatory submissions stall, patient recruitment collapses, and site performance varies
The Electronic Common Technical Document (eCTD) is the global standard for regulatory submissions to health authorities. It uses a structured digital format that improves efficiency and consistency across regions, although each region still has its own requirements. As the world’s
Decentralized clinical trials are reshaping how pharmaceutical and biotech companies conduct research. Instead of requiring patients to visit physical trial sites, DCTs bring the trial to patients via telemedicine, home health visits, wearable devices, and remote monitoring. The approach offers
Taiwan continues to position itself as a fast-growing medical device market in Asia. Supported by a strong healthcare system, an aging population, and rising demand for advanced technologies, the sector is expanding steadily. With a projected compound annual growth rate
